Germany's Stada has expanded its deal with Enymatica to take the latter's ViruProtect common cold brand into Russia, the CIS and beyond.

Consumer health companies are starting to step into the lucrative but fast-changing and complex EU cannabidiol market. But what are the key considerations for firms before making such a move, or if they have already? HBW Insight speaks to CBD regulatory expert Greer Deal. 

Stada's Britannia Pharmaceuticals has acquired Sweden's Lobsor and its Lecigon gel formulation which is already approved in the Nordics and combines levodopa, carbidopa and entacapone infused via a lightweight pump. Meanwhile, Stada has also formed an alliance with MediPharm Labs for medical cannabis.

Stada hires BD and portfolio head; BAH welcomes back Lutz Boden; Anefp extends president's mandate; Ipsen gets BD chief from Merck; and Dr Kade appoints Sirius managing director.